Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome

Shuhei Ito, Shinji Okano, Masaru Morita, Hiroshi Saeki, Satoshi Tsutsumi, Hiroshi Tsukihara, Yuichiro Nakashima, Kouji Andou, Yu Imamura, Kippei Ohgaki, Eiji Oki, Hiroyuki Kitao, Koshi Mimori, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

20 引用 (Scopus)

抄録

Background: Programmed cell death 1 ligand 1 (PD-L1) and human leukocyte antigen (HLA) class I molecules on malignant cell surfaces are pivotal for tumor immunity. The clinical significance of their expression in patients with esophageal squamous cell carcinoma (ESCC) remains to be determined. Methods: PD-L1 and HLA class I protein expression was investigated by immunohistochemical staining of resected specimens from 90 ESCC patients who underwent radical surgery without preoperative therapy. The relationships between the expression of PD-L1 and HLA class I and clinicopathologic factors and patient prognosis were assessed. Results: High expression of PD-L1 and HLA class I were observed in 17 (18.9 %) and 35 (38.9 %) of 90 cases, respectively. High PD-L1 expression was correlated with the depth of tumor invasion (P = 0.0379), lymph node metastasis (P = 0.0031), recurrence (P = 0.0085), and poor overall survival (OS) (5-year survival rate; low/high: 60.9/28.4 %, P = 0.0110). Among those patients with high expression of HLA class I, high PD-L1 expression was correlated with significantly poorer recurrence-free survival (median survival time, low/high: 102.5/3.1 months, P = 0.0016) and poorer OS (median survival time, low/high: 102.5/13.1 months, P = 0.0027). Multivariate analysis showed that combined high PD-L1/high HLA class I expression was an independent prognostic factor for recurrence-free survival (hazard ratio 2.88, 95 % confidence interval 1.02–7.04, P = 0.0455) and OS (hazard ratio 2.95, 95 % confidence interval 1.03–7.50, P = 0.0447). Conclusions: High PD-L1 expression was a significant independent prognostic factor in ESCC patients with high HLA class I expression.

元の言語英語
ページ(範囲)508-515
ページ数8
ジャーナルAnnals of Surgical Oncology
23
DOI
出版物ステータス出版済み - 8 1 2016

Fingerprint

CD274 Antigen
HLA Antigens
Survival
Recurrence
Confidence Intervals
Esophageal Squamous Cell Carcinoma
Immunity
Neoplasms
Multivariate Analysis
Survival Rate
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

これを引用

Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma : Prognostic Factors for Patient Outcome. / Ito, Shuhei; Okano, Shinji; Morita, Masaru; Saeki, Hiroshi; Tsutsumi, Satoshi; Tsukihara, Hiroshi; Nakashima, Yuichiro; Andou, Kouji; Imamura, Yu; Ohgaki, Kippei; Oki, Eiji; Kitao, Hiroyuki; Mimori, Koshi; Maehara, Yoshihiko.

:: Annals of Surgical Oncology, 巻 23, 01.08.2016, p. 508-515.

研究成果: ジャーナルへの寄稿記事

Ito, Shuhei ; Okano, Shinji ; Morita, Masaru ; Saeki, Hiroshi ; Tsutsumi, Satoshi ; Tsukihara, Hiroshi ; Nakashima, Yuichiro ; Andou, Kouji ; Imamura, Yu ; Ohgaki, Kippei ; Oki, Eiji ; Kitao, Hiroyuki ; Mimori, Koshi ; Maehara, Yoshihiko. / Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma : Prognostic Factors for Patient Outcome. :: Annals of Surgical Oncology. 2016 ; 巻 23. pp. 508-515.
@article{4f0ed6ce7b9349b3a5def6690d48f995,
title = "Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome",
abstract = "Background: Programmed cell death 1 ligand 1 (PD-L1) and human leukocyte antigen (HLA) class I molecules on malignant cell surfaces are pivotal for tumor immunity. The clinical significance of their expression in patients with esophageal squamous cell carcinoma (ESCC) remains to be determined. Methods: PD-L1 and HLA class I protein expression was investigated by immunohistochemical staining of resected specimens from 90 ESCC patients who underwent radical surgery without preoperative therapy. The relationships between the expression of PD-L1 and HLA class I and clinicopathologic factors and patient prognosis were assessed. Results: High expression of PD-L1 and HLA class I were observed in 17 (18.9 {\%}) and 35 (38.9 {\%}) of 90 cases, respectively. High PD-L1 expression was correlated with the depth of tumor invasion (P = 0.0379), lymph node metastasis (P = 0.0031), recurrence (P = 0.0085), and poor overall survival (OS) (5-year survival rate; low/high: 60.9/28.4 {\%}, P = 0.0110). Among those patients with high expression of HLA class I, high PD-L1 expression was correlated with significantly poorer recurrence-free survival (median survival time, low/high: 102.5/3.1 months, P = 0.0016) and poorer OS (median survival time, low/high: 102.5/13.1 months, P = 0.0027). Multivariate analysis showed that combined high PD-L1/high HLA class I expression was an independent prognostic factor for recurrence-free survival (hazard ratio 2.88, 95 {\%} confidence interval 1.02–7.04, P = 0.0455) and OS (hazard ratio 2.95, 95 {\%} confidence interval 1.03–7.50, P = 0.0447). Conclusions: High PD-L1 expression was a significant independent prognostic factor in ESCC patients with high HLA class I expression.",
author = "Shuhei Ito and Shinji Okano and Masaru Morita and Hiroshi Saeki and Satoshi Tsutsumi and Hiroshi Tsukihara and Yuichiro Nakashima and Kouji Andou and Yu Imamura and Kippei Ohgaki and Eiji Oki and Hiroyuki Kitao and Koshi Mimori and Yoshihiko Maehara",
year = "2016",
month = "8",
day = "1",
doi = "10.1245/s10434-016-5376-z",
language = "English",
volume = "23",
pages = "508--515",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",

}

TY - JOUR

T1 - Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma

T2 - Prognostic Factors for Patient Outcome

AU - Ito, Shuhei

AU - Okano, Shinji

AU - Morita, Masaru

AU - Saeki, Hiroshi

AU - Tsutsumi, Satoshi

AU - Tsukihara, Hiroshi

AU - Nakashima, Yuichiro

AU - Andou, Kouji

AU - Imamura, Yu

AU - Ohgaki, Kippei

AU - Oki, Eiji

AU - Kitao, Hiroyuki

AU - Mimori, Koshi

AU - Maehara, Yoshihiko

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background: Programmed cell death 1 ligand 1 (PD-L1) and human leukocyte antigen (HLA) class I molecules on malignant cell surfaces are pivotal for tumor immunity. The clinical significance of their expression in patients with esophageal squamous cell carcinoma (ESCC) remains to be determined. Methods: PD-L1 and HLA class I protein expression was investigated by immunohistochemical staining of resected specimens from 90 ESCC patients who underwent radical surgery without preoperative therapy. The relationships between the expression of PD-L1 and HLA class I and clinicopathologic factors and patient prognosis were assessed. Results: High expression of PD-L1 and HLA class I were observed in 17 (18.9 %) and 35 (38.9 %) of 90 cases, respectively. High PD-L1 expression was correlated with the depth of tumor invasion (P = 0.0379), lymph node metastasis (P = 0.0031), recurrence (P = 0.0085), and poor overall survival (OS) (5-year survival rate; low/high: 60.9/28.4 %, P = 0.0110). Among those patients with high expression of HLA class I, high PD-L1 expression was correlated with significantly poorer recurrence-free survival (median survival time, low/high: 102.5/3.1 months, P = 0.0016) and poorer OS (median survival time, low/high: 102.5/13.1 months, P = 0.0027). Multivariate analysis showed that combined high PD-L1/high HLA class I expression was an independent prognostic factor for recurrence-free survival (hazard ratio 2.88, 95 % confidence interval 1.02–7.04, P = 0.0455) and OS (hazard ratio 2.95, 95 % confidence interval 1.03–7.50, P = 0.0447). Conclusions: High PD-L1 expression was a significant independent prognostic factor in ESCC patients with high HLA class I expression.

AB - Background: Programmed cell death 1 ligand 1 (PD-L1) and human leukocyte antigen (HLA) class I molecules on malignant cell surfaces are pivotal for tumor immunity. The clinical significance of their expression in patients with esophageal squamous cell carcinoma (ESCC) remains to be determined. Methods: PD-L1 and HLA class I protein expression was investigated by immunohistochemical staining of resected specimens from 90 ESCC patients who underwent radical surgery without preoperative therapy. The relationships between the expression of PD-L1 and HLA class I and clinicopathologic factors and patient prognosis were assessed. Results: High expression of PD-L1 and HLA class I were observed in 17 (18.9 %) and 35 (38.9 %) of 90 cases, respectively. High PD-L1 expression was correlated with the depth of tumor invasion (P = 0.0379), lymph node metastasis (P = 0.0031), recurrence (P = 0.0085), and poor overall survival (OS) (5-year survival rate; low/high: 60.9/28.4 %, P = 0.0110). Among those patients with high expression of HLA class I, high PD-L1 expression was correlated with significantly poorer recurrence-free survival (median survival time, low/high: 102.5/3.1 months, P = 0.0016) and poorer OS (median survival time, low/high: 102.5/13.1 months, P = 0.0027). Multivariate analysis showed that combined high PD-L1/high HLA class I expression was an independent prognostic factor for recurrence-free survival (hazard ratio 2.88, 95 % confidence interval 1.02–7.04, P = 0.0455) and OS (hazard ratio 2.95, 95 % confidence interval 1.03–7.50, P = 0.0447). Conclusions: High PD-L1 expression was a significant independent prognostic factor in ESCC patients with high HLA class I expression.

UR - http://www.scopus.com/inward/record.url?scp=84977138178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977138178&partnerID=8YFLogxK

U2 - 10.1245/s10434-016-5376-z

DO - 10.1245/s10434-016-5376-z

M3 - Article

AN - SCOPUS:84977138178

VL - 23

SP - 508

EP - 515

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

ER -